Deubiquitinases in cancer

Rongbin Wei _, Xiaodong Liu, Weixin Yu, Tianshu Yang, Wenping Cai, Junjun Liu, Xiao Huang, Guo-tong Xu, Shouliang Zhao, Jianhua Yang and Shangfeng Liu

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:12872-12889. https://doi.org/10.18632/oncotarget.3671

Metrics: PDF 2476 views  |   HTML 3029 views  |   ?  


Rongbin Wei1,*, Xiaodong Liu2,*, Weixin Yu3,*, Tianshu Yang1, Wenping Cai1, Junjun Liu1, Xiao Huang1, Guo-tong Xu1, Shouliang Zhao3, Jianhua Yang1, Shangfeng Liu3

1Department of Ophthalmology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P. R. China

2Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, P. R. China

3Department of Stomatology, Huashan Hospital, Fudan University, Shanghai 200040, P. R. China

*These authors have contributed equally to this work

Correspondence to:

Shangfeng Liu, e-mail: liusf23@gmail.com

Jianhua Yang, e-mail: jianhuay@gmail.com

Shouliang Zhao, e-mail: SLzhao@tongji.edu.cn

Keywords: deubiquitinases, cancer, ubiquitylation, inhibitor

Received: January 16, 2015     Accepted: April 24, 2015     Published: May 07, 2015


Deubiquitinases are deubiquitinating enzymes (DUBs), which remove ubiquitin from proteins, thus regulating their proteasomal degradation, localization and activity. Here, we discuss DUBs as anti-cancer drug targets.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3671